Document is current
Any future updates will be listed below
-
Authors
Okamoto, Yusuke https://orcid.org/0000-0002-9515-8139
Mizumoto, Chisaki
Yamashita, Kouhei
Inoue, Seita
Saito, Susumu
Morimoto, Naoki
Takaori-Kondo, Akifumi
-
Funding
Funding for this research was provided by:
FY2025 Kyoto University Hospital Research Fund for Young Scientists
- License Information
-
More Information
Article History
Received: 10 November 2025
Accepted: 14 February 2026
First Online: 26 February 2026
Declarations
:
: The administration of recombinant activated factor VII (rFVIIa) in this patient with Bernard–Soulier syndrome was an off-label intervention performed under emergency circumstances, as conventional hemostatic therapies had failed to achieve bleeding control. Due to the urgent nature of the situation, formal approval from the institutional review board (IRB) was not obtained prior to treatment. However, the patient was fully informed of the off-label use, potential risks, and anticipated benefits, and provided written informed consent for the treatment. The management was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.
: Informed consent was obtained from the patient for publication of this case report.
: The authors declare no competing interests.
